The Patent Finder

Immunomolecular Therapeutics, Inc.

6 patents currently held · Updated Nov 19, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Mar 2037
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 18, 2027
    The maintenance fee for Methods for producing D-α-methyldopa (US 11,702,383) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
  • 1 fee due Sep 26, 2027
    The maintenance fee for Compounds and Methods for Treating Autoimmune Disorders by Targeting HLA-DQ2 (US 11,939,300) comes due Sep 26, 2027. Unpaid by Mar 27, 2028, it lapses early.
  • 1 fee due Oct 2, 2027
    The maintenance fee for Compounds and methods for treating autoimmune disorders by targeting HLA-DQ2 (US 11,945,790) comes due Oct 2, 2027. Unpaid by Apr 3, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 6 of 6

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,820,957Methods of Treating Autoimmunity
In force
 · High confidence
In forceHigh confidence
US 11,013,707Administration of Oral Methyldopa
In force
 · High confidence
In forceHigh confidence
US 11,052,060Compounds and Methods for Treating Autoimmunity
In force
 · High confidence
In forceHigh confidence
US 11,939,300Compounds and Methods for Treating Autoimmune Disorders by Targeting HLA-DQ2
In force
 · High confidence
In forceHigh confidence
US 11,945,790Compounds and methods for treating autoimmune disorders by targeting HLA-DQ2
In force
 · USPTO record
In forceUSPTO record
US 11,702,383Methods for producing D-α-methyldopa
In force
 · USPTO record
In forceUSPTO record

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

Every application published under this name has become a patent.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited